Nuveen Asset Management, LLC Xenon Pharmaceuticals Inc. Transaction History

Nuveen Asset Management, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$42.66 - $50.04 $89,969 - $105,534	2,109 Added 5.22%	42,473 $1.83 Million
Q4 2023 Feb 14, 2024	SELL	$28.7 - $46.46 $38,199 - $61,838	-1,331 Reduced 3.19%	40,364 $1.86 Million
Q3 2023 Nov 14, 2023	BUY	$34.16 - $39.73 $51,103 - $59,436	1,496 Added 3.72%	41,695 $1.42 Million
Q2 2023 Aug 14, 2023	SELL	$34.84 - $43.54 $456,682 - $570,722	-13,108 Reduced 24.59%	40,199 $1.55 Million
Q1 2023 May 15, 2023	BUY	$33.46 - $40.35 $67,823 - $81,789	2,027 Added 3.95%	53,307 $1.91 Million
Q4 2022 Feb 14, 2023	BUY	$33.06 - $39.43 $30,415 - $36,275	920 Added 1.83%	51,280 $2.02 Million
Q3 2022 Nov 14, 2022	BUY	$30.79 - $39.82 $186,248 - $240,871	6,049 Added 13.65%	50,360 $1.82 Million
Q2 2022 Aug 15, 2022	SELL	$25.44 - $35.16 $139,563 - $192,887	-5,486 Reduced 11.02%	44,311 $1.35 Million
Q1 2022 May 16, 2022	BUY	$25.09 - $33.13 $198,537 - $262,157	7,913 Added 18.89%	49,797 $1.57 Million
Q4 2021 Feb 14, 2022	BUY	$15.6 - $35.4 $196,341 - $445,544	12,586 Added 42.96%	41,884 $1.31 Million
Q3 2021 Nov 12, 2021	SELL	$14.86 - $19.45 $358,958 - $469,834	-24,156 Reduced 45.19%	29,298 $448,000
Q2 2021 Aug 16, 2021	BUY	$16.81 - $20.0 $601,982 - $716,220	35,811 Added 202.98%	53,454 $995,000
Q1 2021 May 17, 2021	BUY	$13.65 - $21.31 $68,836 - $107,466	5,043 Added 40.02%	17,643 $316,000
Q4 2020 May 17, 2021	SELL	$9.49 - $16.04 $119,574 - $202,104	-12,600 Reduced 50.0%	12,600 $194,000
Q4 2020 Feb 16, 2021	BUY	$9.49 - $16.04 $239,148 - $404,208	25,200 New	25,200 $388,000

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.42B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.